Impact of CINV

Prevent chemotherapy-induced nausea and vomiting from the start

Effective prevention at cycle 1 helps to avoid the risk of future CINV events and associated patient management1,2

In a retrospective observational analysis of the electronic health records of 10,586 patients who received single-day chemotherapy1:

~4x CINV risk in subsequent cycles when CINV occurs with cycle 1

(compared to patients with no CINV at cycle 1)

Significant CINV may require additional patient management, including3-10:
In-office hydration, emergency room visits, or reassessment of the chemotherapy regimen

A gap exists in compliance with current antiemetic guidelines for HEC9
In an online survey of 531 oncology nurses evaluating awareness and perceptions of practice adherence to CINV guideline recommendations:

Greatest unmet need Uncontrolled Delayed CINV
Regimens used to prevent delayed CINV (Days 2 to 5) with HEC

75% Were not consistent with antiemetic guideline recommendations

78% Used a 5-HT3 RA, inconsistent with guidelines

5-HT3 RA=5-HT3 receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; HEC=highly emetogenic chemotherapy; NCCN=National Comprehensive Cancer Network.